Clinical KPIs for IBD
From IBD Audit to IBD Registry
In 2017, the national IBD Biological Therapies Audit officially transferred to the IBD Registry from the Royal College of Physicians (RCP). Following a transition period to become an independent not-for-profit company in 2017/18, the IBD Registry resumed publication of the annual Biological Therapies Report in 2019.
IBD Biological Therapies KPIs Programme
The IBD Biological Therapies Programme has focused on the use of biologics in clinical care and reports on a set of validated Biologics Key Performance Indicators (KPIs). It is a continuous programme of data collection and IBD teams are provided with a longitudinal measure of their local KPIs compared to the national average for each, providing them with their own performance change, national change, and local/national comparatives.
Transitioning into the Improving Quality in Crohn’s and Colitis (IQICC) programme
The British Society of Gastroenterology (BSG) IBD Section led a major review of the Biologics Programme and KPIs across 2021 and 2022, with results formally published in Frontline Gastroenterology (June 2023). The review has resulted in a revision of the clinical KPIs and the newly-developed IQICC programme will expand on the work of the Biologics Programme to cover across three focus areas: advanced therapies steroids use, and diagnostic pathway. The IBD Registry is providing the delivery of the programme, including data collection, data analysis and reporting back to IBD teams. There is a transition period to the new national IBD Clinical Audit in 2023-2024, with the IBD Registry supporting IBD teams during the process.
2023 Annual Report on Biological Therapy in IBD
The biological therapy review is a continuous programme of data collection to support clinical quality improvement in the treatment of patients with IBD in the UK. We analyse the data quarterly to provide IBD hospital teams with an ongoing review of clinical performance against the biological therapies KPIs (see top). In addition to this, our data analysis helps provide a picture of how the clinical management of biological therapies is changing on a national level.
Following a major review led by the BSG IBD Section, a revised set of clinical KPIs will be adopted from 2024, and so this report also reflects the upcoming transition from the original set of biologic therapy indicators to a wider set covering diagnostic pathway, appropriate use of steroids and also use of advanced therapies (including biological therapies)
Our 2023 annual report is available below:
Annual Report on Biological Therapy in IBD 2023 (IBD Registry annual report, 2023).
Reports and Publications
The following reports and papers are related to the biological therapies KPIs:
Annual Report on Biological Therapy in IBD 2022 (IBD Registry annual report, 2022).
Annual Report on Biological Therapy in IBD 2021 (IBD Registry annual report, 2021).
Audit of Biological Therapy for inflammatory bowel disease (Gut, 1 June 2019).
Annual Report on Biological Therapy in IBD 2019 (IBD Registry annual report, 2019).